CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool | Sep 24, 2026 9:02 AM EDT

Key PointsCRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editing treatment, CASGEVY.